U.K.-based vaccine developer, Immunobiology Ltd. (ImmBio), has announced that the U.K. government-backed Biomedical Catalyst has awarded the company some £0.2 million (US$0.3 million) to support the pre-clinical development of the company’s PnuBioVax™, a pneumococcal vaccine. According to a news source, the new grant follows a previous Biomedical Catalyst award in late 2012 of approximately £1 million (US$1.5 million) used to further develop ImmBio’s meningococcal B vaccine, MenBioVax™.
“ImmBio is delighted to receive funding from the UK’s innovation agency and Medical Research Council to progress the development of our novel vaccines,” CEO Graham Clarke reportedly said. “Successfully winning funding in both the first and second Biomedical Catalyst investment rounds represents a major vote of confidence in our ImmBioVax™ vaccine technology. This most recent award recognizes the need for effective new vaccines against invasive pneumococcal disease, and the potential of our technology to protect against a wide range of disease-causing strains.” See Heraldonline.com, March 12, 2013.